Detailed description page of THPdb

Details of Th1201 which contains 1 entries.

Entry 1
(1) Primary information
ID 1810
ThPP ID Th1201
Therapeutic Peptide/Protein Name Poractant alfa
Sequence NA view full sequnce in fasta
Functional Classification Ia
Molecular Weight NA
Chemical Formula NA
Isoelectric Point NA
Hydrophobicity NA
Melting Point (℃) NA
Half Life Studied in adult and newborn rabbits, the half-life in the lungs was found to be 25 and 67 respectiv
Description Poractant alfa is a pulmonary surfactant marketed as Curosurf in the United States and Canada. It is used to treat Respiratory Distress Syndrome (RDS) in premature infants with an endogenous pulmonary surfactant deficiency. Poractant alfa is an extract of natural porcine lung surfactant consisting of 99% polar lipids (mainly phospholipids) and 1% hydrophobic low molecular weight proteins (surfactant associated proteins SP-B and SP-C). The phospholipid content of the extract consists primarily of phosphatidylcholine and dipaImitoylphosphatidylcholine. Poractant alfa is a creamy white suspension of this extract in 0.9% sodium chloride solution. It contains no preservatives.
Indication/Disease Poractant alfa is indicated for the treatment of Respiratory Distress Syndrome (RDS) in premature infants.
Pharmacodynamics Poractant alfa improved lung compliance, pulmonary gas exchange and survival in preterm rabbits.
Mechanism of Action Endogenous pulmonary surfactant reduces surface tension at the air-liquid interface of the alveoli in the lungs, thus stabilizing them against collapse under transpulmonary pressures. A deficiency of pulmonary surfactant in premature infants allows surface tension to increase to the point where sections of lung collapse and respiratory distress syndrome (RDS) develops. Poractant alfa lowers minimum surface tension to less than or equal to 4 mN/m. This compensates for the lack of endogenous surfactant and restores adequate surface activity to the lungs
Toxicity Studies on the carcinogenicity or reproductive effects of poractant alfa have not been conducted. Mutagenicity assays were negative. In the case of an overdose with poractant alfa where there are clear clinical effects on the infant's respiration, ventilation, or oxygenation, it is recommended that as much of the solution be aspirated as possible and the infant be managed with supportive measures. Fluid and electrolyte balances should be monitored closely in this case.
Metabolism No studies on the metabolism of poractant alfa have been performed in humans. One small study in rabbits did find that poractant alfa may be degraded by macrophages and that it may, in part, be recycled in the alveoli in a similar manner to endogenous lung surfactant.
Absorption Poractant alfa is administered directly to the site of action in the lungs via endotracheal tube. It very rapidly adsorbs to the air-liquid interface to form a stable surfactant monolayer. No studies on absorption of poractant alfa have been performed in humans.
Volume of Distribution No studies on the distribution of poractant alfa have been performed in humans.
Clearance No studies on clearance of poractant alfa have been performed in humans.
Categories Pulmonary Surfactants
Patents Number NA
Date of Issue NA
Date of Expiry NA
Drug Interaction Bretylium, Ceritinib, Esmolol, Ivabradine, Lacosamide, Octreotide, Ruxolitinib, Tofacitinib
Target
Information of corresponding available drug in the market
Brand Name Curosurf
Company Chiesi USA, Inc
Brand Discription CUROSURF (poractant alfa) is a sterile, non-pyrogenic pulmonary surfactant intended for intratracheal use only. CUROSURF is an extract of natural porcine lung surfactant consisting of 99% polar lipids (mainly phospholipids) and 1% hydrophobic low molecular weight proteins (surfactant associated proteins SP-B and SP-C).
Prescribed for CUROSURFÂ® (poractant alfa) Intratracheal Suspension is indicated for the rescue treatment of Respiratory Distress Syndrome (RDS) in premature infants. CUROSURF reduces mortality and pneumothoraces associated with RDS.
Chemical Name NA
Formulation 80 mg/mL
Physcial Appearance Suspension
Route of Administration endotracheal
Recommended Dosage The initial recommended dose is 2.5 mL/kg birth weight (see Table 1), administered as one or two aliquots depending upon the instillation procedure.
Contraindication NA
Side Effects Curosurf (poractant alfa) Suspension is a pulmonary surfactant used to treat Respiratory Distress Syndrome (RDS) in premature infants. Curosurf reduces mortality and pneumothoraces (collapsed lung) associated with RDS. Common side effects of Curosurf include slow heart rate, low blood pressure, endotracheal tube blockage, and low blood oxygen levels. Many side effects are associated with premature birth.
Useful Link http://www.rxlist.com/curosurf-drug.htm
PubMed ID 17533176, 15813666, 15805381
3-D Structure N.A.

OSDDlinux

Raghava's Group

IMTECH

CSIR

CRDD
CPPSITE 2.0

(1) Primary information
Entry 1
ID	1810
ThPP ID	Th1201
Therapeutic Peptide/Protein Name	Poractant alfa
Sequence	NA view full sequnce in fasta
Functional Classification	Ia
Molecular Weight	NA
Chemical Formula	NA
Isoelectric Point	NA
Hydrophobicity	NA
Melting Point (℃)	NA
Half Life	Studied in adult and newborn rabbits, the half-life in the lungs was found to be 25 and 67 respectiv
Description	Poractant alfa is a pulmonary surfactant marketed as Curosurf in the United States and Canada. It is used to treat Respiratory Distress Syndrome (RDS) in premature infants with an endogenous pulmonary surfactant deficiency. Poractant alfa is an extract of natural porcine lung surfactant consisting of 99% polar lipids (mainly phospholipids) and 1% hydrophobic low molecular weight proteins (surfactant associated proteins SP-B and SP-C). The phospholipid content of the extract consists primarily of phosphatidylcholine and dipaImitoylphosphatidylcholine. Poractant alfa is a creamy white suspension of this extract in 0.9% sodium chloride solution. It contains no preservatives.
Indication/Disease	Poractant alfa is indicated for the treatment of Respiratory Distress Syndrome (RDS) in premature infants.
Pharmacodynamics	Poractant alfa improved lung compliance, pulmonary gas exchange and survival in preterm rabbits.
Mechanism of Action	Endogenous pulmonary surfactant reduces surface tension at the air-liquid interface of the alveoli in the lungs, thus stabilizing them against collapse under transpulmonary pressures. A deficiency of pulmonary surfactant in premature infants allows surface tension to increase to the point where sections of lung collapse and respiratory distress syndrome (RDS) develops. Poractant alfa lowers minimum surface tension to less than or equal to 4 mN/m. This compensates for the lack of endogenous surfactant and restores adequate surface activity to the lungs
Toxicity	Studies on the carcinogenicity or reproductive effects of poractant alfa have not been conducted. Mutagenicity assays were negative. In the case of an overdose with poractant alfa where there are clear clinical effects on the infant's respiration, ventilation, or oxygenation, it is recommended that as much of the solution be aspirated as possible and the infant be managed with supportive measures. Fluid and electrolyte balances should be monitored closely in this case.
Metabolism	No studies on the metabolism of poractant alfa have been performed in humans. One small study in rabbits did find that poractant alfa may be degraded by macrophages and that it may, in part, be recycled in the alveoli in a similar manner to endogenous lung surfactant.
Absorption	Poractant alfa is administered directly to the site of action in the lungs via endotracheal tube. It very rapidly adsorbs to the air-liquid interface to form a stable surfactant monolayer. No studies on absorption of poractant alfa have been performed in humans.
Volume of Distribution	No studies on the distribution of poractant alfa have been performed in humans.
Clearance	No studies on clearance of poractant alfa have been performed in humans.
Categories	Pulmonary Surfactants
Patents Number	NA
Date of Issue	NA
Date of Expiry	NA
Drug Interaction	Bretylium, Ceritinib, Esmolol, Ivabradine, Lacosamide, Octreotide, Ruxolitinib, Tofacitinib
Target
Information of corresponding available drug in the market
Brand Name	Curosurf
Company	Chiesi USA, Inc
Brand Discription	CUROSURF (poractant alfa) is a sterile, non-pyrogenic pulmonary surfactant intended for intratracheal use only. CUROSURF is an extract of natural porcine lung surfactant consisting of 99% polar lipids (mainly phospholipids) and 1% hydrophobic low molecular weight proteins (surfactant associated proteins SP-B and SP-C).
Prescribed for	CUROSURFÂ® (poractant alfa) Intratracheal Suspension is indicated for the rescue treatment of Respiratory Distress Syndrome (RDS) in premature infants. CUROSURF reduces mortality and pneumothoraces associated with RDS.
Chemical Name	NA
Formulation	80 mg/mL
Physcial Appearance	Suspension
Route of Administration	endotracheal
Recommended Dosage	The initial recommended dose is 2.5 mL/kg birth weight (see Table 1), administered as one or two aliquots depending upon the instillation procedure.
Contraindication	NA
Side Effects	Curosurf (poractant alfa) Suspension is a pulmonary surfactant used to treat Respiratory Distress Syndrome (RDS) in premature infants. Curosurf reduces mortality and pneumothoraces (collapsed lung) associated with RDS. Common side effects of Curosurf include slow heart rate, low blood pressure, endotracheal tube blockage, and low blood oxygen levels. Many side effects are associated with premature birth.
Useful Link	http://www.rxlist.com/curosurf-drug.htm
PubMed ID	17533176, 15813666, 15805381
3-D Structure	N.A.